Generation Bio Co.(GBIO)Earnings, Financials & Key Ratios
GBIO•NASDAQ
$5.34
Price updated Jun 20, 2026
AboutGeneration Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$20M+236.9%
- EBITDA-$137M-3.1%
- Net Income-$132M-4.0%
- EPS (Diluted)-19.76-0.7%
- Gross Margin100%
- EBITDA Margin-691.03%+69.4%
- Operating Margin-715.82%+69.5%
- Net Margin-661.91%+69.1%
- ROE-91.02%-74.5%
GBIO Price & Volume
Generation Bio Co. (GBIO) stock price & volume — 10-year historical chart
Loading chart...
Clinical Pipeline Volatility Strains Liquidity Runway
Investment Thesis • Updated 2025Q3
VerdictNegative
Growth:Decelerating
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and clinical dependency
Key Thesis Takeaways
- Generation Bio faces a challenging outlook as its reliance on non-recurring collaboration milestones creates erratic revenue streams that fail to offset persistent, high-intensity R&D spending.
- The company's structural inability to generate positive free cash flow, evidenced by a -33.0% FCF margin in 2025Q3, necessitates a precarious reliance on external capital markets.
- Investors should remain cautious as the rapid erosion of the asset base and a shrinking cash position suggest that significant dilutive financing may be required to sustain long-term clinical development.
Verdict Logic
the company's cash runway is nearing a critical threshold with only $21.9 million in cash remaining, which likely necessitates immediate and dilutive capital market intervention to maintain operations.
GBIO Growth Metrics
Generation Bio Co. (GBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-17.82%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM56.95%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM57.33%
Return on Capital
10 Years-53.37%
5 Years-42.37%
3 Years-42.77%
Last Year-53.63%
Peers Comparison
Key metrics vs top competitors for Generation Bio Co. (GBIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.34 | $35.97M | -0.27 | 236.92% | -661.91% | -91.02% | — | |
| $86.97 | $12.25B | -7128.69 | 23258.15% | -48.38% | -55.09% | — | |
| $4.07 | $444.42M | -2.02 | — | — | -70.79% | — | |
| $35.87 | $3.53B | -6.15 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $368.60 | $10.87B | 53.89 | 33.94% | 53.92% | 19.25% | — |
Compare GBIO vs Peers
Generation Bio Co. (GBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when GBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GBIO Frequently Asked Questions
Generation Bio Co. (GBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Generation Bio Co.'s revenue?
Generation Bio Co. (GBIO) reported $15.3M in revenue for fiscal year 2024. This represents a 42317% increase from $0.0M in 2018.
How fast is Generation Bio Co. growing?
Generation Bio Co. (GBIO) grew revenue by 236.9% over the past year. This is strong growth.
Is GBIO profitable?
Generation Bio Co. (GBIO) reported a net loss of $62.6M for fiscal year 2024.
Dividend & Returns
What is GBIO's return on equity?
Generation Bio Co. (GBIO) has a return on equity (ROE) of -91.0%. Negative ROE indicates the company is unprofitable.
What is Generation Bio Co.'s free cash flow?
Generation Bio Co. (GBIO) had negative free cash flow of $114.7M in fiscal year 2024, likely due to heavy capital investments.